

Your platform for diagnostic success



Meeting the diagnostic c – your choice makes a

With an increasing prevalence of allergy¹ and autoimmune² diseases the need for efficient and accurate diagnoses is growing. Reliable test results of high clinical value are key for optimal clinical decisions.

ImmunoCAP® and EliA™ tests give reliable results that support primary care physicians as well as specialists in providing optimal patient management. Through fully automated Phadia® Laboratory Systems you can increase your operational efficiency and shorten the lead times — whether being a small local clinic or a large commercial laboratory.

Our dedication – your advantage

With our dedication we constantly strive to provide health care professionals with superior diagnostic technologies and clinical expertise to ensure competitiveness and diagnostic sucess.

- Molecular Allergology tests take allergy diagnostics to a whole new level and help clinicians to better diagnose and manage allergy patients.
- We pioneer autoimmunity testing with novel tests and concepts. The broad EliA portfolio includes autoimmunity markers to support the diagnosis of most important autoimmune diseases.
- We continuously develop products and services within areas such as information technology and bioinformatics to add value to your business.

Phadia Laboratory Systems - operational efficiency for any

High productivity strengthened by sharp software solutions, specifically designed to streamline your daily routines and to secure a high instrument uptime.³

- Seamless scalability with instruments for all needs

 from single samples up to 40 000 tests/day
- All instruments on the same tailormade platform with proven reliability and accuracy
- Flexibility to run allergy and autoimmunity assays, in parallel, on the same instrument ⁴
- · Online monitoring and real time communication for efficient support





hallenge difference in patient care

EliA™ – test results with excellent clinical value for early diagnostic guidance in autoimmunity

- Fully automated assays for important autoimmune diseases such as rheumatoid arthritis, celiac disease, inflammatory bowel diseases, connective tissue diseases, antiphospholipid syndrome and vasculitis.
- EliA assays combine exceptional specificity with highest sensitivity.
- Results of diagnostic relevance through clinically validated cut-offs.
- The use of human recombinant antigens of high purity guarantees top quality assays.
- Excellent lot-to-lot consistency ensures high reproducibility of test results.

ImmunoCAP® – making a difference in allergy management

- ImmunoCAP tests include more than 650 standardized, high-quality allergens.
- Unique Molecular Allergology menu contains 90 ImmunoCAP components for the measuring of individual proteins.
- Accurate and precise test results based on a proven assay technology commonly recognized as Gold standard.^{7–9}
- Highly consistent test results over time, geographically between countries and Phadia instruments.
- Acknowledged in international guidelines.

size of laboratory



Phadia^o 1000 Phadia^o 2500 Phadia^o 5000

The technology you choose makes a difference in patient care

- Enhanced patient outcomes in assessment, diagnosis and treatment decisions. 11,12
- Diagnosis is more correct when including results from diagnostic tests.¹³
- Quality of life is improved by a correct diagnosis. 14
- Correct diagnosis saves costs. 15–18

ImmunoDiagnostics – dedication to allergy and autoimmunity diagnostics

For almost 40 years, ImmunoDiagnostics, a part of Thermo Fisher Scientific previously known as Phadia, has maintained global leadership in allergy testing and has become one of the world's leading autoimmune disease test providers. Through clinical excellence, laboratory efficiency and our dedication, we strive to deliver the highest quality and clinical value in our diagnostic tests, as well as providing clinical expertise and scientific information.

References: 1. White Book on Allergy 2011-2012, World Allergy Organization. 2. Peschken CA. et al. Arthritis Res. Ther. 2012; 14(Suppl 3): A20. 3. "Routine operation of new allergy test instrument:enhanced efficiency and significant savings" Nakamura S. Clinical Laboratory International. 2011; October issue. 4. "Automation, consolidation and expansion in allergy diagnosis: embracing the future" Van Rooyen C. Clinical Laboratory International. 2012; February/March issue. **5.** Wood G. Pathology in Practice 2010; Nov: 2–3. **6.** Antico A. et al. Lupus 2010; 19(8): 906–912. **7.** Wood RA et al. Ann Allergy Asthma Immunol. 2007; 99(1): 34–41. **8.** Wang J et al. J Allergy Clin Immunol. 2008; 121(5): 1219–1224. 9. Dolen WK. Allergy. 2003 Aug; 58(8): 717-23. 10. NIH Guidelines on Food Allergy, available at health.nih.gov. 11. Bizarro N et al. Clin Chem. 2007; 53(8): 1527-1533. 12. NIH. Guidelines for the Diagnosis and Management of Asthma, 2007. NIH publication 08 - 4051. 13. NICE Diagnosis and assessment of food allergy in children and young people in primary care and community settings, 2011. http://guidance.nice.org.uk/CG116/Guidance. 14. Gray AM et al. BMC Health Serv. Res. 2010; 10: 105–111. 15. J. Portnoy, Current Allergy and Asthma Reports 2004. **16.** Zethraeus N. et al, Ital J Pediatr. 2010; 36:61. **17.** "Cost-effectiveness of molecular IgE in vitro diagnostics (IVD) in Swedish children suspected with peanut allergy compared to double blind placebo controlled food challenge (DBPCFC)". Hermansson L. et al. 2011, presentation at National HE congress Gothenburg. 18. Mindemark M. "The use of laboratory analyses in Sweden. Quality and cost-effectiveness in test utilization." PhD thesis, Uppsala University 2010.

thermoscientific.com/phadia

© 2013 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific Inc. and its subsidiaries. Manufacturer; Phadia AB, Uppsala Sweden

928-2106 1305 heart.se

